Despite advances in the treatment of myocardial infarction (MI), the incidence of cardiogenic shock has remained at 7% to 10% during the last 25 years. Hospital mortality was about 90% in the ...

Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment ...

SCAI Stage C cardiogenic shock is characterized by significant organ hypoperfusion, necessitating the use of inotropic or ...

The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.

A cardiovascular specialty hospital in north Texas decreased time to diagnosis for patients with cardiogenic shock by more than half, according to a study published in Critical Care Nurse.

We believe that pharmacologic innovation is needed in treating patients with cardiogenic shock,” said Dr. Steve Simonson, CMO and SVP of Windtree. "Currently available drugs can have unwanted side ...

KL4 Surfactant is under clinical development by Windtree Therapeutics and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

The US Food and Drug Administration (FDA ... patients with acute decompensated heart failure (ADHF) and cardiogenic shock. The amendment of PMA specifies the use of the devices for paediatric ...

Nursing staff interventions regarding shock team activation significantly improved the time of diagnosis and acceptance of patients with cardiogenic shock. A cardiovascular specialty hospital in north ...